Abstract 27P
Background
With the development of immune checkpoint inhibitors (ICI), microsatellite instability (MSI) has become an important biomarker. While large multigene hybrid capture next-generation sequencing (NGS) panels are highly accurate in detecting MSI, the sensitivity of small amplicon-based panels is unknown.
Methods
Next-generation sequencing (NGS) was performed on FFPE samples from patients with any stage colorectal cancer (CRC) using the Solo Atlas Pro amplicon panel covering 38 genes and 39 mononucleotide short tandem repeats for MSI analysis. 5-loci polymerase chain reaction (PCR)-based MSI analysis was used as a reference method. MSI by NGS was estimated based on the distribution of k-mers. Statistical analysis was performed using Cohen’s kappa (к), Mann Whitney and Fisher’s exact test.
Results
A total of 160 samples were analyzed using NGS and PCR. Median coverage was 2352x (range, 238-28447х), MAPD – 0.368 (range, 0.236-0.731). Based on PCR results, 42 (46.25%) samples were MSI, 118 (73.75%) – MSS. Based on NGS results, 40 (25%) samples were MSI, 120 (75%) were MSS. NGS and PCR were concordant in 98.75% (158/160) of samples (к=0.97). Sensitivity of NGS was 95.24% (95% CI, 83.84%-99.42%), specificity – 100.00% (96.92%-100.00%), accuracy – 98.75% (95.56%-99.85%). All NGS false positives cases had suboptimal FFPE quality, suggested by absence of any somatic mutations identified. MSI samples had a significantly higher amount of somatic mutations than MSS samples (median, 3 vs 1, p<0.0001). In silico mixing of the sequencing data of 11 MSI samples demonstrated that the minimal sample fraction with the detectable MSI was 0.5%; at 2.5% MSI was detectable in all samples.
Conclusions
The Atlas Pro amplicon panel demonstrates high concordance with PCR and is highly sensitive in detecting MSI in CRC samples.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Russian Science Foundation (Grant №22-75-10154).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
163TiP - Single-institution, single-arm, open-label phase II basket study of mutation and/or elevated hedgehog (Hh) expression-directed smoothened inhibitor sonidegib in patients with advanced solid malignancies
Presenter: Madhawa De Silva
Session: Cocktail & Poster Display session
Resources:
Abstract
164TiP - MONSTAR-GLYCO: A multi-institutional prospective study harnessing glycomics and multi-omics on the j-glyconet and SCRUM-MONSTR platform
Presenter: Tadayoshi Hashimoto
Session: Cocktail & Poster Display session
Resources:
Abstract
166P - Unravelling HR-positive, HER2-negative breast cancer and its tumor microenvironment heterogeneity using spatial transcriptomics
Presenter: Bengisu Karakose
Session: Cocktail & Poster Display session
Resources:
Abstract
167P - Cancer neutrophil encyclopedia: A deep dive into antigen-presenting warriors
Presenter: Yingcheng Wu
Session: Cocktail & Poster Display session
Resources:
Abstract
168P - Tumor microenvironment (TME) and PD-L1 expression heterogeneity in high grade serous ovarian cancer (HGSC) samples analysis from the randomized NeoPembrOV/GINECO phase II trial
Presenter: Laetitia Collet
Session: Cocktail & Poster Display session
Resources:
Abstract
169P - Tumour microenvironment in glioblastoma: A single-cell perspective on macrophage dynamics and T cell exhaustion
Presenter: Farasat Kazmi
Session: Cocktail & Poster Display session
Resources:
Abstract
170P - Digital spatial profiling to uncover biomarkers for response prediction in locally advanced gastric cancer patients treated with neoadjuvant chemotherapy
Presenter: Chiara Molinari
Session: Cocktail & Poster Display session
Resources:
Abstract
171P - Immune-modulatory drug profiling using perfused, microfluidic on-chip co-cultures of patient-derived ovarian cancer microtumors and autologous immune cells
Presenter: Sarah Plöger
Session: Cocktail & Poster Display session
Resources:
Abstract
172P - The impact of androgen ablation on the immune landscape in therapy-resistant prostate cancer: Insights from tumour microenvironment analysis
Presenter: Jodi Stewart
Session: Cocktail & Poster Display session
Resources:
Abstract
173P - NRF2 levels in high grade serous ovarian cancer: Characterization and treatment
Presenter: Helen Toma
Session: Cocktail & Poster Display session
Resources:
Abstract